Jade Biosciences (JBIO) Treasury Shares (2020 - 2026)
Jade Biosciences' (JBIO) quarterly Treasury Shares came in at $307142.0 in Q1 2026, down 98.46% YoY from $20.0 million in Q1 2025, and down 9.52% on a QoQ basis from $339473.0 in Q4 2025.
Jade Biosciences (JBIO) Treasury Shares (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Treasury Shares data on file, last reported at $307142.0 in Q1 2026.
- Quarterly Treasury Shares fell 98.46% year-over-year to $307142.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $307142.0 (down 98.46% YoY) and the FY2025 annual result came in at $339473.0, down 98.3% from the prior year.
- Treasury Shares slipped to $307142.0 in Q1 2026, from $339473.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $28.9 million in Q4 2022 to a low of $19192.0 in Q1 2024.
- A 5-year average of $6.5 million and a median of $307142.0 in 2026 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2023 — Treasury Shares tumbled 99.92% — and 2025, when it surged 104110.09%.
- Tracing JBIO's Treasury Shares over 5 years: stood at $28.9 million in 2022, then plunged by 99.92% to $21968.0 in 2023, then jumped by 90941.51% to $20.0 million in 2024, then sank by 98.3% to $339473.0 in 2025, then decreased by 9.52% to $307142.0 in 2026.
- The last three Treasury Shares figures came in at $307142.0 (Q1 2026), $339473.0 (Q4 2025), and $371804.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | 274,811.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 274,811.00 |
| Jun 30, 2026 | 274,811.00 |
| Mar 31, 2026 | 307,142.00 |
| Mar 31, 2026 | 307,142.00 |
| Dec 31, 2025 | 339,473.00 |
| Dec 31, 2025 | 339,473.00 |
| Sep 30, 2025 | 371,804.00 |
| Sep 30, 2025 | 371,804.00 |
| Jun 30, 2025 | 495,739.00 |
| Jun 30, 2025 | 495,739.00 |
| Mar 31, 2025 | 20.00 Mn |
| Mar 31, 2025 | 20.00 Mn |
| Dec 31, 2024 | 20.00 Mn |
| Dec 31, 2024 | 20.00 Mn |
| Sep 30, 2024 | 20.00 Mn |
| Sep 30, 2024 | 20.00 Mn |
| Jun 30, 2024 | 20.00 Mn |
| Jun 30, 2024 | 20.00 Mn |
| Mar 31, 2024 | 19,192.00 |
| Mar 31, 2024 | 19,192.00 |